ArticleTherapeutics and clinical risk management2020

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience.

Yi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.